clinical significance for quality of life endpoints in clinical trials
Download
Skip this Video
Download Presentation
Clinical Significance for Quality of Life Endpoints in Clinical Trials

Loading in 2 Seconds...

play fullscreen
1 / 33

Clinical Significance for Quality of Life Endpoints in Clinical Trials - PowerPoint PPT Presentation


  • 171 Views
  • Uploaded on

Jeff A. Sloan, Ph.D. Mayo Clinic, Rochester, MN, USA. Clinical Significance for Quality of Life Endpoints in Clinical Trials. FDA/Industry Statistics Workshop Washington, September 16, 2005. Primary goal: advance the state of the science to help cancer patient QOL soar.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Clinical Significance for Quality of Life Endpoints in Clinical Trials' - judith


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
clinical significance for quality of life endpoints in clinical trials

Jeff A. Sloan, Ph.D.

Mayo Clinic, Rochester, MN, USA

Clinical Significance for Quality of Life Endpoints in Clinical Trials

FDA/Industry Statistics Workshop

Washington, September 16, 2005

take home message there is good news
Take home message:there is good news
  • There are problems with using QOL assessments as indicators of efficacy in clinical trials.
  • There are scientifically sound solutions to these problems. The problems have been disseminated widely and consistently. The solutions have not.
slide5

Science is a candle in the dark

- Carl Sagan

We will use the candle of science to improve the QOL of cancer patients

slide6

How do you determine

the clinical significance

of QOL assessments?

why is it difficult to define clinical significance for qol
Why is it difficult to define “clinical significance” for QOL?
  • Pain analogy
    • 25 years ago physicians were the sole raters of patient pain
    • JCAHO 2000 guideline: every patient’s pain to be assessed upon intake on a 0-10 scale
  • Time and experience alleviates novelty and skepticism, and guidelines evolve
why is it difficult to define clinical significance for qol9
Why is it difficult to define “clinical significance” for QOL?
  • Blood pressure analogy
    • 100 years ago, clinical significance of BP scores was unknown (Lancet 1899)
    • massage therapy was the gold standard
    • present guidelines for BP clinical significance today redrawn (McCrory DC. Lewis SZ. Chest. 126(1 Suppl):11S-13S, 2004)
the solution found for tumor response cutoffs may provide guidance
The solution found for tumor response cutoffs may provide guidance
  • We call a reduction of 50% a response.
  • Have reductions of 49% all the time, but do not worry about misclassification.
  • Moertel (1976) basis for 50% cutoff
  • Find a cutoff and stick to it? (RECIST)
what clinical significance is not
What Clinical significance is NOT
  • Statistical significance
  • Example drawn from JCO 2001 (anonymous)
    • HSQ before / after scores on 1300 patients
    • all p-values <0.0001
    • conclusion: all domains of QOL were significantly different across treatment groups
    • problem: 1300 patients provides 80% power to detect a change of 1 unit on 0-100 point scale
eortc qlq lc13
EORTC QLQ-LC13
  • Item n=537 n=346 Effect Size
  • Coughing 46.2 44.3 small
  • Dyspnea 17.2 16.2 small
  • Pain 26.9 25.5 small
  • all p-values were statistically significant
the six papers
The Six Papers
  • 1) Methods used to date
  • 2) Group versus individual differences
  • 3) Single item versus multi-item
  • 4) Patient, clinician, population perspectives
  • 5) Changes over time
  • 6) Practical considerations for specific audiences
  • MCP, April, May, June 2002
slide16

No single statistical decision rule or procedure can take the place of well-reasoned consideration of all aspects of the data by a group of concerned, competent, and experienced persons with a wide range of scientific backgrounds and points of view.

Canner (1981)

If it looks like a duck, sounds like a duck, and walks like a duck, the odds of it being a worm or an elephant in a clever disguise are small in the extreme.

Sloan (2001)

bottom line
Bottom Line
  • Assessing the clinical significance of QOL can be as simple as a 10-point change on a 100-point scale, if that is consistent with the goals of the scientific enquiry. The real issue underlying the controversy over QOL is the relative novelty and lack of experience that presently exists with QOL. With time and familiarity this too shall pass.

(Sloan, J Chronic Obs. Pul. Dis. 2: 57-62, 2005.)

two general methods for clinical significance
Two general methods for clinical significance
  • Anchor-based methods requirements
    • independent interpretable measure (the anchor) which has appreciable correlation between anchor and target
  • Distribution-based methods
    • rely on expression of magnitude of effect in terms of measure of variability of results (effect size)
the empirical rule effect size eres approach sloan et al cancer integrative medicine 1 1 41 47 2003
The Empirical Rule Effect Size (ERES) Approach (Sloan et al, Cancer Integrative Medicine 1(1):41-47, 2003)
  • QOL tool range = 6 standard Deviations
  • SD Estimate =100 percent / 6

= 16.7% of theoretical range

  • Two-sample t-test effect sizes (J Cohen, 1988):

small, moderate, large effect(0.2, 0.5, 0.8 SD shift)

  • S,M,L effects = 3%, 8%, 12% of range
the empirical rule
The Empirical Rule
  • Tchebyshev’s Theorem: at least 1-1/k2 of any distribution will fall within k standard deviations (SD’s) of the mean
  • If the distribution is symmetric, 99% will fall within 3 standard deviations
  • The pdf for the range is a function of the SD
  • an estimate of the SD can be obtained via
    • range = 6 SD
assumption checking for eres dueck sloan 2006 j biopharm stats in press
Assumption Checking for ERES(Dueck, Sloan, 2006, J. Biopharm. Stats, in press)
  • Tchebyshev’s Inequality is conservative
  • Tested the effect of various distributional assumptions
  • Only a uniform distribution results in deviation from the assumption of a 6 SD-based estimate (28% instead of 17%)
all methods give similar answers
All Methods Give Similar Answers
  • Cohen - 1/2 SD is moderate effect
  • MCID - 1/2 point on 7-point Likert
    • 7-1 = 6 point range ==> SD of 1 unit
    • so 1/2 point ==:> 1/2 SD
  • Cella - 10 point on FACT-G
    • 10/1.12 = 8.9% / 16.7% = 1/2 SD
  • Feinstein - correlation approach
    • Cohen was arbitrary, should be 0.6 SD
the good news
The Good News
  • Statistical, Philosophical, Empirical, Clinical, Historical, Practical approaches to defining a clinically significant effect for symptom assessments are all in the same ballpark
  • A 10 point difference on a 100-point scale (1/2 SD) is almost always going to be clinically significant
  • Smaller differences may also be meaningful (data)
  • Applies to groups or individuals (just different SD)

Norman GR, Sloan JA, Wyrwich KW. Expert Review of Pharmacoeconomics and Outcomes Research Sept 2004; 4(5): 515 – 519

Sloan JA, Cella D, Hays R. J Clin Epidemiol (in press).

four guidelines sloan cella hays jce 2005 in press
Four Guidelines(Sloan, Cella, Hays, JCE 2005,in press)
  • The method used to obtain an estimate of clinical significance should be scientifically supportable.
  • The ½ SD is a conservative estimate of an effect size that is likely to be clinically meaningful. An effect size greater than ½ SD is not likely to be one that can be ignored. In the absence of other information, the ½ SD is a reasonable and scientifically supportable estimate of a meaningful effect.
four guidelines sloan cella hays jce 2005 in press28
Four Guidelines(Sloan, Cella, Hays, JCE 2005,in press)
  • Effect sizes below ½ SD, supported by data regarding the specific characteristics of a particular QOL assessment or application, may also be meaningful. The minimally important difference may be below ½ SD in such cases.
  • If feasible, multiple approaches to estimating a tool’s clinically meaningful effect size in multiple patient groups are helpful in assessing the variability of the estimates. However, the lack of multiple approaches with multiple groups should not preemptively restrict application of information gained to date.
summary
Summary
  • Defining clinical significance for QOL assessments is today where pain was 25 years ago, tumor response was 50 years ago and blood pressure was 100 years ago
  • Define clinical significance a priori, and use the definition in the analytical process
  • Consensus is building as the answers from different approaches are similar and relatively robust
slide31
A Mayo/FDA meeting regardingguidance on patient-reported outcomes (PRO)Discussion, Education, and Operationalization
  • FDA to release guidances for assessing PRO’s in all clinical trials (3rd quarter 2005?)
  • Meeting co-sponsored with FDA to:
    • provide a focused process to facilitate discussion among all stakeholders
    • educate stakeholders on background, content, and concerns
    • provide an opportunity for input
    • delineate ways to best operationalize the guidance into clinical trials
  • February 23-25, 2006, DC (Westfields Marriott, Chantilly, VA, 7 miles from Dulles)
ad